Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins
Cheol‐Min Park(Abbott (United States)), Steven W. Elmore(AbbVie (United States)), Kennan C. Marsh(AbbVie (United States)), Xilu Wang(AbbVie (United States)), Jessica Adickes(Abbott Fund), Milan Bruncko(Abbott Fund), Michael Wendt(Abbott Fund), Aaron Kunzer(Abbott Fund), Hong Ding(Abbott (United States)), Xiaohong Song(Abbott (United States)), Haichao Zhang(Abbott Fund), Xiufen Yang(Abbott Fund), Stephen K. Tahir(Abbott Fund), Alexander R. Shoemaker(Abbott Fund), Christin Tse(Abbott Fund), Joy Bauch(Abbott Fund), Stephen W. Fesik(Vanderbilt University), Saul H. Rosenberg(Abbott Fund), Paul Nimmer(Abbott Fund)
Cited by 293
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k